Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00953667 · ClinicalTrials.gov registry record · NA
The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 400
- Enrollment target
NCT00953667: Completed NA study, sponsored by University of Pennsylvania.
NCT00953667 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 400 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00953667, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of this study is to determine genetic factors that affect responses to niacin therapy and endotoxemia in healthy volunteers.
Interventions
- DRUG Immediate Release Niacin, Extended Release Niacin, Endotoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2007-06 |
| Est. Completion | 2011-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00953667
The ClinicalTrials.gov registry entry for NCT00953667 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Immediate Release Niacin, Extended Release Niacin, Endotoxin is the first listed.
NCT00953667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00953667 about?
NCT00953667 is a clinical study titled "The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study". The purpose of this study is to determine genetic factors that affect responses to niacin therapy and endotoxemia in healthy volunteers.
What is the current status of trial NCT00953667?
This trial is currently completed. It is a NA study. The enrollment target is 400 participants. The study started on 2007-06. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00953667?
The interventions under investigation include: Immediate Release Niacin, Extended Release Niacin, Endotoxin (DRUG).
Who is sponsoring clinical trial NCT00953667?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.